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ABSTRACT
Objective: Although the beneﬁts of coronary stenting
have been demonstrated in several large clinical trials,
controversy remains as to whether stenting results in
long-term cost savings compared to percutaneous trans-
luminal coronary angioplasty (PTCA). The objective of
this study was to evaluate the resource use and cost
(Medicare payment) of PTCA versus bare stent in actual
practice over a 2-year period.
Methods: The data for this study came from the 1996
through 1998 Standard Analytic Files that contain 5% of
Medicare claims. The rates of repeat revascularization
procedures and hospitalizations were reported at 1 and 2
years. Costs associated with inpatient admission, out-
patient procedures, physician services, skilled nursing
facility admissions, and home health-care services were
included to perform a comprehensive assessment. Regres-
sion analysis was performed to test for cost differences
controlling for case-mix variation between the patient
groups.
Results: The selection process yielded 3782 PTCA
patients and 2690 stent patients for analysis. The rate of
revascularization was 26.7% for the PTCA group and
22.2% for the stent group at 2 years. The mean total cost
for the initial procedure was $13,724 for PTCA and
$15,021 for stenting. At 2 years, the total cumulative cost
was $32,654 for the PTCA group and $32,102 for the
stent group, a difference that was not statistically
signiﬁcant.
Conclusion: Although the difference in the rate of repeat
revascularization procedures between PTCA and stenting
is not as large as those reported in clinical trials, bare
stents are cost-neutral when compared to PTCA for the
Medicare population.
Keywords: claims data, cost, Medicare, PTCA, stent.
Introduction
Coronary stent placements have grown rapidly over
the past decade, and currently over 80% of all angi-
oplasties performed in the United States involve
stent placement. Although the beneﬁts of coronary
stenting have been demonstrated in several large
clinical trials, controversy remains as to whether
stenting results in long-term cost savings compared
to percutaneous transluminal coronary angioplasty
(PTCA). A search of the published literature
revealed studies that showed stenting and PTCA to
have similar long-term costs [1–3] and those that
conclude that stenting remained more expensive [4–
6].
Proponents of coronary stenting have argued
that although stenting is initially more expensive,
the reduced need for repeat procedures produces
comparable cost between stent and PTCA over the
long term. Therefore, the lower cost after discharge
makes up for the higher initial procedural cost. Sev-
eral studies based on clinical trials have reported on
the reduced need for repeat revascularization rates
associated with stent placement [7–9], which lends
support for lower cost among stent patients in the
period after discharge compared to PTCA patients.
These ﬁndings have been questioned by some clini-
cians, Topol, for example [10], and recent studies
analyzing data from clinical practice setting con-
cluded that there were no signiﬁcant differences in
revascularization rates between stent placement and
PTCA [11,12]. These authors conclude that stent
placement results in higher overall cost compared to
PTCA and question the cost-effectiveness of stent
placement.
Therefore, although the effectiveness and cost of
stent placements have been extensively studied in
clinical trials, there still remains much debate over
the long-term cost of coronary stent placement in
everyday practice setting. Previous studies that have
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evaluated stenting in clinical practice have had short
follow-up and therefore may not have captured the
entire cost differential associated with the proce-
dures in the period after discharge [11–13]. In addi-
tion, no study to date has performed an assessment
including costs of all health-care services provided
to these patients. Despite this lack of cost assess-
ment, coronary stenting has been adopted rapidly
with over 70% of percutaneous coronary interven-
tion involving stent placement. The cost-effective-
ness of this practice needs to be evaluated and with
the imminent launch of coated stents such an assess-
ment is even more critical. Coated stents have
shown to dramatically reduce restenosis rates in
recent clinical trials but are expected to cost signif-
icantly more than bare stents. Coated stents are pro-
jected to cannibalize the market for bare stents
when introduced and therefore it is important to
evaluate the cost-effectiveness of current practice,
PTCA versus bare stents, to compare coated stents
against the most cost-effective option.
The objective of this study was to evaluate the
resource use and cost of PTCA versus bare stent in
actual practice over a 2-year period and discuss
implications for coated stents. The analysis was per-
formed from the perspective of the largest payer for
health-care services in the United States, the Center
for Medicare & Medicaid Services (CMS). Cost to
the Medicare program, therefore, payment made to
hospitals, was analyzed and the focus of the analysis
was on the elderly population eligible for Medicare,
those 65 years and older. Health-care claims were
analyzed to obtain resource use and cost informa-
tion from normal practice rather than clinical trial
setting. Costs associated with inpatient admission,
outpatient procedures, physician services, skilled
nursing facility admissions, and home health-care
services were included to perform a comprehensive
assessment.
Methods
The data for this study came from the 1996 through
1998 Standard Analytic Files created by the CMS.
These ﬁles contain a 5% nationwide random sam-
ple of Medicare claims for inpatient, outpatient,
physician ofﬁce, skilled nursing facility, and home
health-care services. We excluded patients who were
less than 65 years old or who lived outside the
United States. In addition, to ensure complete
record of all services, we excluded patients who
were enrolled in an HMO, who did not have both
Part A and Part B coverage, and for whom Medi-
care was not the primary payer. When transfer
occurred between hospitals, the records where
combined to indicate a single admission to avoid
duplication. A programmer performed all data
manipulation in SAS with signiﬁcant experience in
Medicare claims data analyses. The data were man-
ually reviewed after each step in the analytic ﬁle
construction process to ensure accuracy in the pro-
gramming performed.
The International Classiﬁcation of Diseases, 9th
Revision, Clinical Modiﬁcation (ICD-9-CM) codes
were used to identify angioplasty (36.01, 36.02, and
36.05) and stent (36.01, 36.02, and 36.05) proce-
dures that were performed in 1996. Data were
abstracted for these patients for a 2-year period.
Because we did not always have information on
date of service, the 2-year follow-up period was
deﬁned as eight consecutive quarters starting with
the quarter in which the index admission occurred.
To ensure that patients were continuously enrolled
in fee-for-service plans, only those with at least one
contact with the medical system in 1997 and 1998
were included in the analysis. A very small propor-
tion, 2% of stenting and 3% of the angioplasties,
occurred in the outpatient setting. Patients with
these outpatient procedures were eliminated from
the study sample, partly to avoid the uncertainty on
whether these were truly outpatient or whether they
lacked full data.
To compare case-mix differences between the
two groups, the Charlson index adapted for use
with administrative databases was calculated
[14,15]. The Charlson index is a summation of
weighted comorbid conditions demonstrated to be
strong predictors of cardiovascular-related morbid-
ity and mortality [16,17]. The variables contained
in the Charlson index and their weights (given in
parenthesis) are as follows: peripheral vascular
disease (1); chronic lung disease (1); dementia (1);
chronic liver disease (1); peptic ulcer disease (1);
diabetes mellitus with no sequelae (1); diabetes
mellitus with sequelae (2); renal failure (2); leuke-
mia, lymphoma, or solid cancer (2); liver disease
with sequelae (3); and metastatic cancer or multiple
cancers (6). The presence of these conditions was
identiﬁed for each individual during the index
admission and over the 2-year follow-up period. In
addition to the Charlson index, the proportion of
patients admitted with myocardial infarction (MI)
and those who underwent multivessel procedures
was abstracted. Demographic information, includ-
ing age, sex, and race, was summarized for patients
in both groups.
The short-term resource use parameters analyzed
are same-admission coronary artery bypass graft
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(CABG), index admission length of stay, and dis-
charge to skilled nursing facility (SNF) or home
health-care services. The rate of repeat revasculari-
zation procedures (PTCA, stent, CABG) is reported
at 1- and 2-year follow-up for the PTCA and stent
groups. The percentage of individuals with hospi-
talizations for MI and other reasons, outpatient
visits, physician ofﬁce visits, SNF stays, and home
health-care services usage is also reported. As
appropriate, the average number of visits and the
length of stay are provided.
Index admission and 2-year cumulative costs
were also estimated. Medicare payments are used as
a proxy for cost and the estimates provided, there-
fore, reﬂect the cost to the Medicare program. In
1996, the Medicare inpatient payments for PTCA
and stent placement were the same, and payment
changes to reﬂect differences in resource use
between the two procedures were not implemented
until 1998. In 1998, the average reimbursement for
stent placement was $1259 more than for PTCA.
We increased the 1996 Medicare reimbursement to
hospitals for stent placement by $1219 (1998 dif-
ference adjusted for inﬂation using hospital services
component of Consumer Price Index) to reﬂect the
higher cost associated with the stent procedure.
Inpatient, outpatient, physician, skilled nursing
facility, home health-care services, and total costs
were estimated.
All case-mix, resource use, and cost measures
generated were tested for statistically signiﬁcant dif-
ferences between the PTCA and stent group using
either a Student’s t test or chi-square test as appro-
priate. Statistical signiﬁcance at the 5% level is gen-
erally reported, unless otherwise noted. Regression
analysis was performed to test for differences in 2-
year revascularization rate and cost controlling for
patient case mix. Logistic regression was estimated
to assess differences in revascularization, and ordi-
nary least squares regression was utilized to study
impact on cumulative 2-year cost. Log cost was also
attempted to identify whether this provided a better
ﬁt. The independent variables were age, sex, race,
Charlson index, MI at index admission, and treat-
ment group (stent/PTCA).
Results
The selection process yielded 3782 PTCA patients
and 2690 stent patients for analysis. A comparison
of the patient characteristics and risk factors are
provided in Table 1. There are some differences in
age and race across the groups. The PTCA patients
were older (43.1% vs. 39.2% were 74 years or
older) and more likely to be nonwhite (7.8% vs.
5.7%). It should be noted that although these dif-
ferences are statistically signiﬁcant, the magnitude
of the differences is not large. PTCA cases also had
a signiﬁcantly greater proportion of MIs (30.5% vs.
25.1%) and diabetes (31.5% vs. 28.1%). On the
other hand, stent patients had signiﬁcantly greater
number of cases with unstable angina (44.0% vs.
48.9%). Stent patients also had a larger number
of multivessel procedures (11.7% vs. 13.2%), but
this was not a statistically signiﬁcant result at the
5% level; signiﬁcant at the 10% level. There were
no signiﬁcant differences in the proportion with
peripheral vascular disease or renal disease and in
the overall comorbidity as measured by the Charl-
son index.
Resource use indicators for the acute phase, or
index admission, are reported in Table 2. Same-
admission CABG, not controlling for patient differ-
ences, is much higher for the PTCA group than the
stent group. Overall, 3.4% of patients in the PTCA
group had a CABG performed during the index
admission compared to 1.3% in the stent group.
The PTCA group had a signiﬁcantly higher rate of
in-hospital mortality compared to the stent group
(3.3% vs. 1.8%). Although a higher proportion of
PTCA patients were discharged to SNFs (3.2% vs.
Table 1   Patient characteristics and risk factors
PTCA
(n = 3782)
Stent
(n = 2690)
Age (%)*
65–69 27.0 29.2
70–74 29.9 31.7
74–79 25. 23.8
80–84 13.1 12.3
>84 4.6 3.0
Sex (% women) 44.1 41.9
Race (%)*
White 92.2 94.3
Black 4.4 3.3
Other 2.6 1.8
Unknown 0.8 0.6
Multivessel procedure (%) 11.7 13.2
Number of selected comorbid conditions
AMI* 30.5 25.1
Diabetes* 31.5 28.1
Unstable angina* 44.0 48.9
Peripheral vascular disease 12.2 11.7
Renal disease 5.1 5.2
Charlson index (number of conditions)†
0 30.1 31.0
1 27.5 28.3
2 18.2 17.8
3 10.3 10.3
4 or more 13.9 12.6
*Signiﬁcant at the 5% level.
†Measured over a 2-year period.
Source: Medicare 5% Standard Analytic File (SAF), 1996–1998.
Abbreviations: AMI, acute myocardial infarction; PTCA, percutaneous translu-
minal coronary angioplasty.
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2.5%), this is not a statistically signiﬁcant differ-
ence. Both groups have the same proportion of dis-
charges to home health-care services (8.5%) and no
difference in average index admission length of stay
of 5 days.
The 1- and 2-year resource use parameters
shown in Table 3 reveal several differences between
the PTCA and the stent groups. Any revasculariza-
tion, which includes PTCA, stent placement, or
CABG, at 2 years was 26.7% for the PTCA group
and 22.2% for the stent group. This difference is
statistically signiﬁcant and the gap between PTCA
and stent groups increased from 2% at 1 year to
4.5% at 2 years. The difference between the two
groups is largely driven by the higher rate of CABG
surgery among the PTCA patients compared to the
stented patients. At the 2-years follow-up, 10.3% in
the PTCA group had CABG surgery versus 6.9% in
the stent group. In addition, in the 2-year postpro-
cedure period, stent patients had a slightly lower
rate of PTCA (11.0% vs. 10.4%) and stent place-
ment (9.4% vs. 8.4%).
The rate of hospital admissions over the 2-year
follow-up, whether MI-related or an admission for
any condition, was very similar between the two
groups. The average length of stay, however, was
higher for the PTCA group compared to the stent
group (6.8 days vs. 5.9 days), and this difference
was statistically signiﬁcant at the 5% level. Overall,
about half of the patients with hospitalizations, a
total of 58.4% for PTCA group and 56.1% for
stent group, were admitted either for a revasculari-
zation procedure or as a result of a MI. There were
no differences in either the rate or the number of
outpatient clinic visits. Nevertheless, PTCA patients
used more SNF and home health-care services.
Among PTCA patients, the rate of SNF and home
health-care services usage was 7.0 and 27.1%,
respectively, and for stent patients it was 5.7 and
24.2%, respectively.
As expected, PTCA patients had on average
lower cost associated with the index admission than
stent patients. The mean total cost for the PTCA
group was $13,724 and for the stent group it
was $15,021, a statistically signiﬁcant difference
(Table 4). This difference does not persist in the fol-
low-up period and the 2-year total cumulative cost
was $32,654 for the PTCA group compared to
Table 2 Acute-phase outcomes and resource use
parameters
PTCA
(n = 3782)
Stent
(n = 2690)
Same-admission CABG (%)* 3.4 1.3
In-hospital mortality (%)* 3.3 1.8
Discharge to SNF (%) 3.2 2.5
Discharge to home health-care
services (%)
8.5 8.5
Length of stay (days) 5.0 (4.4) 5.0 (4.2)
*Signiﬁcant at the 5% level.
Source: Medicare 5% Standard Analytic File (SAF), 1996–1998.
Abbreviations: CABG, coronary artery bypass graft; PTCA, percutaneous
transluminal coronary angioplasty; SNF, skilled nursing facility.
Table 3 Long-term resource use
1 year 2 years
PTCA Stent PTCA Stent
Any revascularization (%)*† 18.3 16.3 26.7 22.2
PTCA 6.8 7.6 11.0 10.4
Stent 6.0 5.8 9.4 8.4
CABG*‡ 7.9 4.9 10.3 6.9
Hospital admissions
MI hospitalization (%) 3.8 3.8 5.6 5.5
Percentage with any admission 38.0 41.3 58.4 56.1
Average length of stay (days)*§ 4.0 4.1 6.8 5.9
Outpatient visits
Percentage with outpatient visit 64.0 70.7 92.1 91.7
Number of outpatient visits§ 4.3 5.0 7.7 7.6
SNF
Percentage with SNF use* 4.2 3.9 7.0 5.7
SNF length of stay (days)*§ 0.9 0.8 1.6 1.2
Home health-care services
Percentage using home health-care services* 17.6 17.7 27.1 24.2
Number of home health-care visits*§ 0.8 0.8 1.5 1.1
*Signiﬁcant at the 5% level at 2 years.
†Includes PTCA, stent, or CABG.
‡Includes same admission CABG.
§Reported across all individuals.
Source: Medicare 5% Standard Analytic File (SAF), 1996–1998.
Abbreviations: CABG, coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty; SNF, skilled nursing facility.
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$32,102 for the stent group. Cost of inpatient serv-
ices makes up a large proportion, over 70% of the
total 2-year cost. The cost of outpatient services,
SNF stays, and home health-care services account
for 10%, or approximately $3500, of the total
cumulative cost. Although there were statistically
signiﬁcant differences in SNF and home health-care
usage, these differences were not reﬂected in costs
related to these services between the two groups.
Signiﬁcant differences were found in cost of out-
patient care and physician services, although the
magnitude of these differences was small, approxi-
mately $250 in both cases.
Multivariate analyses of differences in cumula-
tive 2-year revascularization rate and cost of PTCA
versus stenting are presented in Table 5. Patients
with stent placement were signiﬁcantly less likely to
require revascularization compared to PTCA
patients after controlling for case-mix differences,
with an odds ratio of 0.77. Although age was not
consistently signiﬁcant, patients 65 to 74 years were
more likely to undergo repeat revascularization pro-
cedures that those >80 years. White patients were
about 1.5 times more likely to have a revasculari-
zation procedure in the 2-year follow-up period
than nonwhite persons. Revascularization rates
increased with the number of comorbidities.
Patients with four or more clinical conditions as
measures by the Charlson index were 1.4 times
more likely to have a procedure than those with any
conditions. Sex and acute MI (AMI) at admission
did not impact repeat revascularization rate.
After controlling for case-mix differences the
PTCA and stent groups did not differ in cumulative
2-year cost. As shown in the regression results pre-
sented in Table 5, age, sex, race, and Charlson index
impacted cost signiﬁcantly, whereas AMI at admis-
sion and the indicator of stent versus PTCA did not
result in any difference. Younger patients were less
expensive ($1883 to $2460), women had lower cost
than men ($2274), and white patients had lower
cost than other races ($3454). The more the number
of clinical conditions identiﬁed by the Charlson
index, the greater the cost. A patient with one con-
dition had a total cost of $3965 more than a patient
with no conditions, and similarly a patient with
four or more conditions was $23,996 more expen-
sive. Overall, stent placement was cost-neutral.
Although initially more expensive, stenting resulted
in signiﬁcantly lower cost in the period after dis-
charge, which helped offset the high index proce-
dural cost.
To test the robustness of the results presented
above, we performed both sensitivity and subgroup
analyses. We had increased the cost of stenting in
1996 by $1219 based on the difference between
PTCA and stenting in 1998. Increasing the cost of
stenting by up to an additional $550 would not
change the conclusions reached but costs greater
than this will result in lower 2-year cumulative costs
for PTCA versus stenting. As indicated in Table 1,
there were differences in patient characteristics and
risk factors between the groups. Speciﬁcally, PTCA
patients had a higher proportion of MI and diabe-
tes, which may place PTCA patients at a higher risk
for complications and restenosis. We had included
MI in the multivariate analysis to control for dif-
ferences between PTCA and stent patients, but
Table 4 Index admission and 2-year cost*
Index admission Follow-up period Two-year cumulative† 
PTCA Stent PTCA Stent PTCA Stent
Inpatient‡§ $11,728 $12,925 $10,402 $9,378 $22,130 $22,303
(6,030) (5,436) (16,066) (14,173) (17,720) (15,857)
Outpatient|| — $2,247 $2,001
(4,375)
$2,247
(3,506)
$2,001
(4,375)
(3,506)
Physician§||¶ $1,996 $2,096 $4,706 $4,365 $6,702 $6,461
(1,380) (1,249) (4,587) (4,120) (4,927) (4,401)
SNF — — $497
(2,649)
$389
(2,387)
$497
(2,649)
$389
(2,387)
Home health care — — $1,078
(4,151)
$948
(4,529)
$1,078
(4,151)
$948
(4,529)
Total§ $13,724 $15,021 $18,930 $17,081 $32,654 $32,102
*Standard deviations reported in parentheses.
†Includes cost of index admission.
‡Payments adjusted to reﬂect cost of stent.
§Signiﬁcant at the 5% level for index admission.
||Signiﬁcant at the 5% level at 2 years.
¶Includes payment for services provided in the inpatient, outpatient, and ofﬁce setting.
Source: Medicare 5% Standard Analytic File (SAF), 1996–1998.
Abbreviations: PTCA, percutaneous transluminal coronary angioplasty; SNF, skilled nursing facility.
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diabetes was only included as a component of the
Charlson index. To eliminate any bias that may
result from the higher levels of diabetes in the PTCA
group, we performed the same regression excluding
all patients with diabetes in both groups. The results
remain the same with no differences in the 2-year
cost between PTCA and stent patients.
Discussion
This study evaluated the 2-year resource use and
cost of bare stent placement versus PTCA in the
actual practice setting. At 2-year follow-up, stent
patients were signiﬁcantly less likely to undergo
repeat revascularization procedures after control-
ling for case-mix differences. Much of this differ-
ence is due to the lower rate of both emergent
and elective CABG surgery among stent patients.
Although stent patients had a signiﬁcantly lower
rate of repeat revascularization procedures, the dif-
ference of 4.5% at 2 years is much smaller than
those reported in many clinical trials. One possible
explanation is that stent patients in clinical trials
may have been different from those who undergo
stent placement in actual clinical practice. If this is
the case, then we can expect the repeat revascular-
ization rates between PTCA and stent patients in
this study to differ from those reported in controlled
clinical trials. In addition, stent technology has
evolved over the years, and therefore the outcomes
associated with newer stents and deliver systems
could be better.
Stent and PTCA patients did not differ in the rate
of hospitalization or outpatient visits during the fol-
low-up period but stent patients stayed fewer days
on average. Stent patients also had a signiﬁcantly
lower rate of SNF admissions and home health-care
service usage. Not controlling for patient differ-
ences, the 2-year cost for stent patients was
$32,102, and for PTCA patients it was $32,654.
After controlling for differences in patient charac-
teristics and risk factors, the regression estimates
indicate that there are no cost differences between
PTCA and bare stent patients. The index procedure
cost was $1297 higher for stent patients but the sig-
niﬁcantly lower cost for stent patients compared to
Table 5 Differences in 2-year revascularization rate and cost controlling for risk factors
Variables
Two-year cumulative
revascularization rate*
Two-year cumulative  
cost† 
Parameter
estimate (SE) Odds ratio Chi-square
Parameter  
estimate (SE) t statistic
Stent (vs. PTCA) −0.26 0.77 19.01‡ −$84 −0.14
(0.06) (583)
Age (vs. those >80 years)
65–69‡ 0.39 1.48 17.41‡ −$2,460 −2.75*
(0.09) (895)
70–74‡ 0.35 1.42 14.95‡ −$2,309 −2.64*
(0.09) (874)
75–79§ 0.11 1.12 1.42 −$1,883 −2.08§
(0.10) (907)
Female (vs. male)‡ 0.03 1.03 0.28 −$2,274 −3.9‡
(0.06) (583)
White (vs. other races)‡ 0.44 1.56 12.6* −$3,454 −3.05‡
(0.13) (1,134)
Charlson index (vs. those 
without conditions)
One condition‡ 0.19 1.22 6.31¶ $3,965 5.28‡
(0.08) (751)
Two conditions‡ 0.23 1.26 7.02‡ $8,395 9.85‡
(0.09) (852)
Three conditions‡ 0.33 1.39 10.14‡ $13,715 13.3‡
(0.10) (1,033)
Four or more conditions‡ 0.36 1.44 14.77‡ $23,996 25.49‡
(0.09) (942)
AMI (versus no AMI at admission) −0.04 0.97 0.29 −$793 −1.24
(0.06) (638)
Intercept −1.86 142.58* $31,828 22.30‡
(0.16) (1,445)
*Estimated by logistic regression.
†Estimated by ordinary least squares regression. R2 for model was .112.
‡Signiﬁcant a the 1% level.
§Signiﬁcant at the 5% level.
Source: Medicare 5% Standard Analytic File (SAF), 1996–1998.
Abbreviations: AMI, acute myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty.
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PTCA patients in the follow-up period offsets the
higher initial cost. Although about 50% of the cost
savings resulted from lower inpatient cost, a sub-
stantial 25% was from lower cost associated with
outpatient, SNF, and home health-care services.
Therefore, the inclusion of cost for provision of
services in the nonhospital setting is important in
analyzing the differences between PTCA and stent
patients. These costs have not been included in pre-
vious assessments and should be included especially
when studying the elderly population.
The results presented in this study focused on the
resource use and costs associated with stenting ver-
sus PTCA. In evaluating these two procedures, it is
important to consider the ﬁndings from this study in
relation to the outcomes such as mortality and
health-related quality of life associated with each
procedure. For this study population, the in-hospi-
tal mortality, not controlling for patient differences,
was 3.3% for PTCA and 1.8% for stents. We did
not have mortality information for the follow-up
period and therefore cannot ascertain whether this
difference persisted over the long term and after
controlling for patient differences.
This study analyzed claims data and therefore
clinical information related to location, size, and
type of lesion treated were not available. The
absence of clinical data results in several limitations
that need to be highlighted. First, because we do not
have details on lesion treated, our revascularization
rates are not directly comparable to the target lesion
revascularization reported in clinical studies. The
revascularization rate reported in this study could
include interventions performed on lesions other
than those targeted during the index intervention.
Second, we do not have information on the resten-
osis rate, and therefore comparisons were solely
based on rate of repeat interventions. Third, we
tried to control for differences in patient risk factors
between the two groups but may not have been able
to account for all factors because they are often
underreported in claims data. The PTCA group may
have included more high-risk patients than the stent
group and therefore a comparable group of PTCA
patients to stent patients may have resulted in lower
costs associated with PTCA than those reported in
this study.
The Medicare program perspective was adopted
in this study and therefore payment information
and not hospital cost was reported. A potential lim-
itation is that although Medicare payments are
supposed to represent hospital cost, they may not
always accurately reﬂect the true cost of providing
care in a hospital setting. In addition, the data did
not allow for costs associated with other treatments
that may have been provided in addition to PTCA
or stenting during the inpatient admission, for
instance, thrombolytic therapy, to be reported sep-
arately. We therefore could not account for cost dif-
ferences between the two groups that may have
resulted from the use of adjunct interventions.
In conclusion, bare stents appear to be cost-neu-
tral when compared to PTCA for the Medicare pro-
gram. Although stents have a signiﬁcantly higher
index procedure cost, cost savings in the follow-up
period offset the higher initial cost. Costs associated
with use of skilled nursing facility, home health
care, and outpatient services are a signiﬁcant con-
tributor to overall cost of these patients. The dif-
ferences in repeat revascularization procedures
although lower for stent patients were not as large
as those reported in clinical trials. It is therefore
important that studies outside of the clinical trial
setting, controlling for differences in practice pat-
terns, type of lesion treated, and patient risk factors,
be performed to evaluate the long-term costs and
outcomes associated with new stent technology
such as coated stents.
This study was supported by GlaxoSmithKline.
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